Clinical Trial

Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor

Study acronym: GERTRUDE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to learn if certain drug combinations are effective treatments for patients with advanced ER+/HER2- who have previously been treated with palbociclib, ribociclib, or abemaciclib.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-06-28; most recent amendment 2026-01-16.
Status change: Not Yet Recruiting → Recruiting 2023-10-24
Trial Details
NCT Number NCT05933395
Lead Sponsor Dartmouth-Hitchcock Medical Center
Conditions Advanced Breast Cancer
Enrollment 135 participants
Start Date 2024-09-23
Primary Completion 2030-10 (estimated)
Study Completion 2031-10 (estimated)
Updated on ClinicalTrials.gov 2026-01-20